Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 3/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773476 | 0.95 | DRD2 (0.46) | KCNH2CHRM4SIGMAR1DRD2DRD4 | |
| SCHEMBL5771833 | 0.89 | DRD2 (0.42) | CHRM4DRD2DRD4UBE2MDCUN1D1 | |
| SCHEMBL5774454 | 0.80 | SIGMAR1 (0.41) | CHRM4SIGMAR1ACHE | |
| Trifluoroacetic Acid SCHEMBL5771823 | 0.79 | SIGMAR1 (0.58) | CHRM4SIGMAR1DRD2DRD4UBE2M | |
| SCHEMBL5776141 | 0.77 | TRPV1 (0.37) | — | |
| Trifluoroacetic Acid SCHEMBL5773475 | 0.76 | DRD4 (0.58) | SIGMAR1DRD2DRD4BCHEACHE | |
| Trifluoroacetic Acid SCHEMBL5773674 | 0.75 | OPRM1 (0.47) | DRD2DRD4UBE2MDCUN1D1OPRM1 | |
| Trifluoroacetic Acid SCHEMBL5774584 | 0.74 | MEN1 (0.44) | KCNH2CHRM4DRD2DRD4OPRM1 | |
| SCHEMBL5774218 | 0.73 | OPRM1 (0.50) | DRD2DRD4UBE2MDCUN1D1OPRM1 | |
| SCHEMBL5907124 | 0.73 | FAAH (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | KCNH2 1149/4885CHRM4 1437/4885SIGMAR1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.